JournalsHub
.online
Find My Journal
AS

Andre C. Schuh

Independent Researcher

ORCID 0000-0003-2869-852X
363
Publications
17,186
Citations
46
H-Index
126
i10-Index
7.23
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Fouad Shalaby, Janet Rossant, Terry P. Yamaguchi, Marina Gertsenstein, Xiang‐Fu Wu +2 more
Nature 1995
3,939
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia OA
Hagop Kantarjian, Anthony S. Stein, Nicola Gökbuget, Adele K. Fielding, Andre C. Schuh +21 more
New England Journal of Medicine 2017
2,040
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia OA
Liran I. Shlush, Sasan Zandi, Amanda Mitchell, Weihsu Claire Chen, Joseph Brandwein +20 more
Nature 2014
1,414
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts OA
Hervé Dombret, John F. Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag +19 more
Blood 2015
1,138
A Requirement for Flk1 in Primitive and Definitive Hematopoiesis and Vasculogenesis OA
Fouad Shalaby, Jacqueline Ho, William L. Stanford, Klaus-Dieter Fischer, Andre C. Schuh +3 more
Cell 1997
918

Publications

363 total

Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

H. Döhner, Andre C. Schuh, C. Recher, Jenny O'Nions, Ibrahim Aldoss - Transplantation and Cellular Therapy, 2026
Cited by 0 Semantic Scholar

Real‐world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia

Brian Leber, Marcia T. Ruiz, Hany Elgendy, F. Pettersson, T. Prebet - Cancer, 2025
Cited by 0 Semantic Scholar

Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial.

E. Jabbour, F. Lussana, P. Martínez-Sánchez, Anna Torrent, J. Rifon - The Lancet Haematology, 2025
Cited by 8 Semantic Scholar

POSTER: AML-110 Patients With Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results From the Revumenib Phase 2 AUGMENT-101 Study

Martha L. Arellano, M. Thirman, J. DiPersio, M. Heiblig, Eytan M. Stein - Clinical Lymphoma, Myeloma & Leukemia, 2025
Cited by 0 Semantic Scholar

Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia OA

V. Pullarkat, K. Pratz, H. Döhner, Christian Récher, M. Thirman - Blood Cancer Journal, 2025
Cited by 4 Semantic Scholar

Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review

David I Marks, R. Cassaday, Josep-Maria Ribera, Andre C. Schuh, Jae H. Park - Expert Review of Hematology, 2025
Cited by 1 Semantic Scholar

Identifying people with acute lymphoblastic leukemia who are most suitable for treatment with inotuzumab ozogamicin: a plain language summary

David I Marks, R. Cassaday, Josep-Maria Ribera, Andre C. Schuh, Jae H. Park - Expert Review of Hematology, 2025
Cited by 0 Semantic Scholar

AML-110: Patients With Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results From the Revumenib Phase 2 AUGMENT-101 Study

Martha L. Arellano, M. Thirman, J. DiPersio, M. Heiblig, Eytan M. Stein - Clinical Lymphoma, Myeloma & Leukemia, 2025
Cited by 0 Semantic Scholar

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Martha L. Arellano, M. Thirman, J. Dipersio, M. Heiblig, E. Stein - Blood, 2025
Cited by 33 Semantic Scholar

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine OA

H. Döhner, K. Pratz, C. Dinardo, Andrew H. Wei, B. Jonas - Blood, 2024
Cited by 100 Semantic Scholar

Research Topics

Acute Myeloid Leukemia Research (250) Chronic Myeloid Leukemia Treatments (96) Acute Lymphoblastic Leukemia research (95) Myeloproliferative Neoplasms: Diagnosis and Treatment (79) Chronic Lymphocytic Leukemia Research (30)

Frequent Co-Authors

HA
Hartmut Döhner
5 joint publications
MA
Mark D. Minden
4 joint publications
VI
Vikas Gupta
3 joint publications
AA
Aaron D. Schimmer
3 joint publications
KA
Karen Yee
3 joint publications
CH
Christian Récher
3 joint publications

Affiliations

Ontario Institute for Cancer Research
CA 2013 - 2002
Goethe University Frankfurt
DE 2017 - 2017
Universitat Autònoma de Barcelona
ES 2017 - 2017
Mount Sinai Hospital
CA 2017 - 1992
City Of Hope National Medical Center
US 2017 - 2017

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now